COVID-19 Vaccine & Therapeutics Tracker
See the latest updates for vaccine and therapeutic drug developments for COVID-19. Check back for regular updates!
New addition counters are reset every Monday by 11:59 PM ET. Last updated November 6, 2020 at 6:55PM ET
Vaccines
179
TOTAL
56
IN HUMAN TRIALS
Therapeutic Drugs
437
+4
TOTAL
350
+4
IN HUMAN TRIALS
Activity FeedLive updates on vaccine and therapeutic drug developments
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="255" height="258"><rect fill-opacity="0"/></svg>)
CT-P59 treatment resulted in at least 44% faster recovery time when compared with placebo control in phase 1 clinical trial results of COVID-19 patients with mild symptoms
November 6, 2020
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="174" height="171"><rect fill-opacity="0"/></svg>)
Johnson and Johnson extends Ad26.COV2.S phase 3 clinical trials to multiple sites around the world with an additional 30,000 participants.
November 4, 2020
Wuhan Institute of Biological Products and Sinopharm expand phase 3 clinical trials of their inactive SARS-CoV-2 vaccine to Peru.
November 3, 2020
NVX-CoV2373 phase 3 clinical trials expand with 30000 additional participants in The United States of America, Mexico and Puerto Rico.
November 2, 2020
CureVac’s CVnCoV was generally well tolerated across all tested doses and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation in interim data from an ongoing Phase 1 clinical trial.
November 2, 2020
IIBR-100 , a new replicating COVID-19 vaccine developed by the Israel Institute for Biological Research, starts phase 1/2 clinical trials in Israel.
October 29, 2020
Regeneron’s REGN-COV2 significantly reduced viral load and patient medical visits according to prospective results from an ongoing Phase 2/3 clinical trial in the COVID-19 outpatient.
October 28, 2020
Interim analysis of LY-CoV555 , Eli Lilly’s neutralizing antibody, indicated that one of three doses appeared to accelerate the natural decline in SARS-CoV-2 viral load over time, whereas the other doses had not in a New England Journal of Medicine publication of their phase 2 clinical trial.
October 28, 2020
Johnson & Johnson to Resume Phase 3 clinical trial of its COVID-19 Vaccine Candidate, Ad26.COV2.S , in The United States of America.
October 23, 2020
The United States of America Food and Drug Administration authorises restart of the COVID-19 AZD1222 (ChAdOx1 nCoV-19) vaccine phase 3 clinical trial.
October 23, 2020
Remdesivir* , which has been authorized for use on an emergency basis since spring, was officially approved by US regulators as the first treatment for COVID-19.
October 22, 2020
Tocilzumab did not increase patients' chances of survival or help them get better faster according to two studies while a third less definitive trial did find the drug increased the chances of survival. All studies were published in the Journal of the American Medical Association.
October 20, 2020
A new adenoviral-based vaccine, hAd5-S-Fusion+N-ETSD , developed by ImmunityBio, Inc enters phase 1 clinical trials in The United States of America.
October 19, 2020
Entos Pharmaceutical’s Covigenix VAX-001 enters phase 1 clinical trials in Canada, a DNA plasmid vaccine encoding the viral nucleocapsid antigen.
October 19, 2020
BNT162b2, one of BioNTech and Pfizer’s COVID-19 vaccine candidates, starts phase 1 clinical trials in Japan.
October 19, 2020
Remdesivir, Hydroxychloroquine, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine, Lopinavir/ Ritonavir* and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine, Lopinavir* /Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir, Hydroxychloroquine*, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Remdesivir* , Hydroxychloroquine, Lopinavir/Ritonavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay according to the WHO solidarity trial meta-analysis results published in a preprint server of 11,266 adults across 30 countries in 405 hospitals.
October 15, 2020
Avidaptil treated patients survived 81% of the time beyond 60 days compared to 17% of control patients according to topline efficacy data from a 45-participant open-label prospective study of critically ill COVID-19 patients with severe comorbidities completed by NeuroRx and Relief therapeutics.
October 13, 2020
Phase 3 clinical trials for Johnson & Johnson's COVID-19 vaccine candidate, Ad26.COV2.S , have been put on hold due to an ‘unexplained illness’ observed in a study volunteer
October 13, 2020
Eli Lilly’s phase 3 trial of its monoclonal antibody treatment, LY-CoV555 , has been paused due to potential safety concerns.
October 13, 2020
Novavax’s protein subunit vaccine, NVX-CoV2373 , starts phase 3 clinical trials in the United Kingdom in combination with the seasonal influenza vaccine.
October 12, 2020
A combination of Ivermectin and Doxycycline was shown to improve Early Clinical scores in patients with mild to moderate COVID-19 compared to placebo control in non-peer-reviewed results posted by Dhaka Medical College.
October 9, 2020
Sinovac’s inactive vaccine, CoronaVac , enters phase 3 clinical trials in Turkey with an estimated enrollment of 13,000 participants.
October 9, 2020
A final report by the ACTT-1 Study Group on Remdesivir* in a double-blind, randomized, placebo-controlled trial of 1029 adults who were hospitalized with Covid-19 was published in the New England Journal of Medicine indicating a shortening of the time to recovery and evidence of lower respiratory tract infection compared to placebo control.
October 8, 2020
A small-scale observational study published in the journal Rheumatology indicates that In patients with moderate to severe SARS-CoV-2 pneumonia a combination of Baricitinib* with corticosteroids was associated with greater improvement in pulmonary function when compared with corticosteroids alone.
October 6, 2020
A study published in The Lancet indicates that the antiviral drugs Lopinavir* and Ritonavir*, were not associated with reductions in mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death in patients admitted to hospital with COVID-19.
October 5, 2020
Results published in Nature of a 60-person subset of BioNTech and Pfizers ongoing Phase 1/2 clinical trials of their BNT162b1 vaccine demonstrates that immunized individuals generate a robust SARS-CoV-2-sepcific antibody and cellular mediated immune response which suggests multiple mechanisms with potential to protect against COVID-19.
September 30, 2020
Merck Sharp & Dohme Corp.’s second COVID-19 vaccine, V590 , enters Phase 1 clinical trials in the United States of America.
September 30, 2020
The Results of Moderna and NIAID’s mRNA-1273 vaccine Phase 1 clinical trial in older adults (56+ years of age) published in the New England Journal of Medicine reveals a robust antibody and cellular immune response in vaccinated individuals.
September 29, 2020
The Universitätsklinikum Hamburg-Eppendorf’s Modified Vaccinia Ankara virus vaccine, MVA-SARS-2-S , enters Phase 1 clinical trials in Germany.
September 29, 2020
Regeneron Pharmaceuticals announces preliminary data from 275 patients in its Phase 1/2/3 clinical trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.
September 29, 2020
INOVIO’s Phase 2/3 Clinical trial of its COVID-19 vaccine candidate, INO-4800 , has been put on partial clinical hold until questions posed by the U.S. FDA about the candidate and the delivery device (CELLECTRA® 2000) have been satisfactorily addressed. This hold is not due to the occurrence of any adverse events.
September 28, 2020
Chulalongkorn University’s mRNA vaccine, ChulaCov19 , enters Phase 1 clinical trials in Thailand.
September 28, 2020
Vaxart’s non-replicating Ad5 vector SARS-CoV-2 vaccine VXA-CoV2-1 enters Phase I clinical trials in the United States of America.
September 24, 2020
In a press release, FUJIFILM Toyama Chemical Co. announced the results of their Phase 3 clinical trial of Favipiravir* , whereby non-severe pneumonia COVID-19 patients that received the drug had a shorter time to negative conversion of detectable SARS-CoV 2 viral RNA compared to placebo control.
September 23, 2020
AstraZeneca and the University of Oxford’s Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) has yet to resume in the United States where the FDA is reported to be requesting further data on the two adverse reactions.
September 20, 2020
Roche announced that their Phase 3 study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Tocilizumab* plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care.
September 18, 2020
Eli Lilly announced proof of concept data from an interim analysis of LY-CoV555 , a SARS-CoV-2 neutralizing antibody, in their Phase 2 clinical trial, showing a reduced rate of hospitalization, improved viral clearance, and no drug-related serious adverse events for outpatients in the treatment group.
September 16, 2020
A new multi-peptide based vaccine, CoVac-1 , developed by The University Hospital Tuebingen enters Phase 1 clinical trials in Germany.
September 14, 2020
Imperial College of London Researchers will begin testing the safety and efficacy of both LNP-nCoVsaRNA and The University of Oxford/AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) when administered by inhalation in a 30 patient initial cohort.
September 14, 2020
Initial data released by Eli Lilly and Incyte from the Adaptive COVID-19 Treatment Trial indicates that Baricitinib* in combination with remdesivir reduced time to recovery by approximately one-day and improved patient outcomes at Day 15 when compared with remdesivir alone.
September 14, 2020
The Phase 3 clinical trial of AZD1222 (ChAdOx1 nCoV-19) resumes after the conclusion of an independent review process and following the recommendations of both the independent safety review committee and the United Kingdom Medicines and Healthcare products Regulatory Agency.
September 12, 2020
COVAXX and United Biomedical Inc.’s protein subunit vaccine, UB-612 start Phase 1 clinical trials in Taiwan.
September 11, 2020
Novavax starts Phase 3 clinical trials of its COVID-19 vaccine candidate, NVX-CoV2373 , in the United Kingdom.
September 11, 2020
Vir Biotechnology, Inc and GlaxoSmithKline’s SARS-CoV-2 neutralizing antibody, VIR-7831 , enters phase 2/3 clinical trials.
September 10, 2020
Preclinical data of Pfizers and BioNTech’s RNA-based vaccine, BNT162b2 [ BNT162(b1,b2,b3) ], published in the preprint server bioRxiv indicate a robust antibody and T cell response in both mice and non-human primates further validating its ongoing human clinical trials.
September 8, 2020
The University of Oxford and AstraZeneca’s Phase 3 study testing their vaccine candidate, AZD1222 (ChAdOx1 nCoV-19) , was put on hold due to a suspected serious adverse reaction in a United Kingdom trial participant.
September 8, 2020
Sinovac Biotech states that CoronaVac , its inactive coronavirus vaccine candidate, appeared to be safe for older people, while the elicited immune responses were slightly weaker than for younger adults, according to preliminary results from an early to mid-stage trial.
September 7, 2020
CanSino Biologics’ Ad5-nCoV vaccine starts Phase 3 clinica trials in Russia.
September 7, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) starts Phase 3 clinical trials in Russia.
September 7, 2020
Gilead Sciences starts Phase 1/2 clinical trial testing of inhaled Remdesivir* in patients with early-stage SARS-CoV-2 disease.
September 4, 2020
Sanofi and GlaxoSmithKline’s unnamed protein subunit vaccine [ Unnamed Protein Subunit Vaccine - Sanofi/GSK ] enters phase 1/2 clinical trials in the United States.
September 3, 2020
BioNTech’s BNT162b3 [ BNT162(b1,b2,b3) ] enters Phase 1/2 clinical trials in Germany.
September 2, 2020
A meta-analysis of 1703 patients published in The Journal of the American Medical Association demonstrated that administration of systemic corticosteroids [ Corticosteroid Therapy* ] (including dexamethasone, hydrocortisone, or methylprednisolone) was associated with lower 28-day all-cause mortality compared with usual care or placebo.
September 2, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) enters Phase 3 clinical trials in Brazil, with an anticipated enrollment of 5000 participants.
September 2, 2020
A publication in the New England Journal of Medicine indicates that Novavax’s NVX-CoV2373 appears to be safe, and elicits both a strong antibody and cellular response against SARS-CoV-2.
September 2, 2020
Results from Sanofi and Regeneron’s Phase 3 clinical trials indicate no statistically significant reduction in hospital stay duration or time to improved clinical outcomes in COVID-19 patients treated with Sarilumab* . The companies do not anticipate conducting further clinical studies using this drug.
September 1, 2020
BeiGene’s anti-coronavirus antibody, BGB DXP593 , enters Phase 1 clinical trials.
September 1, 2020
Pfizers’ SARS-CoV-2 specific antiviral [ PF-07304814 ] enters Phase 1 clinical trials.
September 1, 2020
Novavax’s protein subunit vaccine NVX-CoV2373 enters Phase 2 clinical trials in South Africa.
August 31, 2020
Mabwell Bioscience Co.’s new anti-coronavirus antibody, MW33 , enters Phase 1 clinical trials.
August 31, 2020
Gam-COVID-Vac enters Phase 3 clinical trials in Russia, with an expected enrollment of 40,000 participants.
August 28, 2020
QazCovid-in , an inactive viral vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan enters Phase 1/2 clinical trials.
August 28, 2020
An Unnamed Recombinant Vaccine developed by Jiangsu Province Centers for Disease Control and Prevention and West China Hospital enters Phase 1 clinical trials.
August 28, 2020
A gorilla adenovirus-based vaccine, GRAd-COV2 , developed by ReiThera Srl and Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani enters Phase 1 clinical trials in Italy.
August 27, 2020
CanSino Biologics Inc. and Beijing Institute of Biotechnology’s adenovirus-based vaccine candidate, Ad5-nCoV , enters Phase 3 clinical trials in Pakistan.
August 26, 2020
Russia’s second vaccine, EpiVacCorona , enters Phase 1 / 2 clinical trials.
August 25, 2020
A publication in the Journal Clinical Infectious Diseases outlines the first genetic evidence-confirmed case of reinfection with SARS-CoV-2.
August 25, 2020
Convalescent plasma is given Emergency Use Authorization by the U.S. FDA for treatment of patients with COVD-19. Preliminary data suggests a potential beneficial effect, however, solid evidence is lacking.
August 23, 2020
The shingles vaccine, Shingrix , enters Phase 1 clinical trials as a preventative agent in elderly individuals for its hypothesized non-specific immunomodulatory effects.
August 21, 2020
Adimmune’s protein subunit vaccine AdimrSC-2f enters Phase 1 clinical trials in Taiwan.
August 21, 2020
A preprint publication of Phase 1 clinical trial results in the US supports the selection of Pfizer and BioNTech’s BNT162b2 [ BNT162(b1,b2,b3) ] vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation.
August 20, 2020
A Phase 3 trial of the University of Oxford and AstraZeneca’s SARS-CoV-2 vaccine, AZD1222 (ChAdOx1 nCoV-19) , starts in The United States of America in collaboration with Iqvia Pty Ltd with an expected enrollment of 30,000 participants.
August 18, 2020
CureVac AG’s investigational SARS-CoV-2 mRNA vaccine ( CVnCoV ) enters Phase 2 clinical trials.
August 17, 2020
An interim report of Phase 1/2 trials of the Unnamed Inactive Vaccine - Wuhan Published in the Journal JAMA indicates that patients had a low rate of adverse reactions and demonstrated high neutralizing antibody titers.
August 13, 2020
Preliminary results from an ongoing Phase 1/2 clinical trial published in the journal Nature indicate that BNT162b1 [ BNT162(b1,b2,b3) ] is safe, tolerable, and elicits a robust neutralizing antibody response to SARS-CoV-2 in 45 healthy adult participants.
August 12, 2020
A preprint publication of interim analysis indicated that Colchicine* reduced the length of both, supplemental oxygen therapy and hospitalization in a randomized, double-blinded, placebo-controlled clinical trial of 35 patients with moderate to severe COVID-19.
August 12, 2020
Russia becomes the first country to grant regulatory approval to a coronavirus vaccine, gam-COVID-vac, prior to its completion of clinical trials.
August 11, 2020
AstraZeneca’s therapeutic combination of monoclonal antibodies against the SARS-CoV-2 spike protein, AZD7442 , enters Phase 1 clinical trials.
August 11, 2020
Sinovac’s inactive vaccine, CoronaVac , was well-tolerated and immunogenic in a preprint publication of Phase 2 clinical trial results that were conducted in a Randomized, Double-blind, and Placebo-controlled fashion in 600 healthy adults.
August 10, 2020
Janssen Vaccine’s Ad26.COV2.S enters Phase 3 clinical trials, with an estimated enrollment of 60,000 participants worldwide.
August 10, 2020
The Corticosteroid Therapy* , Methylprednisolone, was associated with increased ventilator-free days and a higher probability of extubation in a propensity-score matched cohort study of 42 participant pairs published in the journal Clinical Infectious Diseases.
August 9, 2020
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate, NVX-CoV2373 , for local production and commercialization in Japan.
August 7, 2020
Vaccination with NVX-CoV2373 was generally well-tolerated, induced neutralization antibody titers in 100% of participants, and elicited a robust cellular response in Novavax’s 131 participant Phase 1 clinical trial results.
August 4, 2020
Merck’s V591 , a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector, enters Phase 1 clinical trials.
August 4, 2020
TMV-083 , a vaccine that uses a live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2 enters Phase 1 clinical trials.
August 4, 2020
Eli Lilly and AbCellera’s antibody against the SARS-CoV-2 spike protein, LY3819253, enter Phase 3 clinical trials in the United States.
August 4, 2020
Preliminary results have demonstrated that Aviptadil aided in rapid recovery from respiratory failure in the most critically ill patients with COVID-19 in an ongoing Phase 2/3 clinical trial sponsored by NeuroRx, Inc. and Relief Therapeutics.
August 3, 2020
A study published in Nature shows the SARS-CoV-2 vaccine Ad26.COV2.S elicits a strong immune response that protects against subsequent infection in a non-human primate model.
July 30, 2020
In a press release by Inovio, INO-4800 demonstrated the longest-term protection in non-human primates SARS-CoV-2 challenge model (13 weeks post-vaccination). The immunization also elicited antibodies that neutralize newer viral variants.
July 30, 2020
AZD1222 (ChAdOx1 nCoV-19) elicited a robust immune response in two animal models and prevented pneumonia in a non-human primate model of SARS-CoV-2 infection according to a publication in the journal Nature. However, there was no difference in nasal shedding between vaccinated and control animals.
July 30, 2020
Tocilizumab* failed to improved clinical status in patients with COVID-19 associated pneumonia, or reduced patient mortality in a randomized, double-blind, placebo-controlled phase 3 trial by Roche. The clinical trial program will continue to further explore the drug in other settings, including in combination with an antiviral.
July 29, 2020
The European Union purchases $73.9 million worth of Remdesivir* from Gilead, enough to treat 30,000 patients.
July 29, 2020
Health Canada authorizes the use of Remdesivir* in patients with severe COVID-19 symptoms.
July 28, 2020
BioNTech and Pfizer decide upon BNT162(b1,b2) [ BNT162(b1,b2,b3) ] as their candidate vaccines of choice moving forward in Phase 2/3 clinical trials. This study will include up to 30,000 participants at 120 sites worldwide.
July 27, 2020
MVC-COV1901 , a protein subunit vaccine developed by Medigen Vaccine Biologics Corp. enters Phase 1 clinical trials in Taiwan.
July 27, 2020
Arcturus Therapeutics’ RNA-based vaccine LUNAR-COV19 (ARCT-021) enters Phase 1/2 clinical trials in Singapore.
July 22, 2020
The antiviral drug Favipiravir* demonstrated faster viral clearance compared to the control arm and no severe adverse events in a press release by Glenmark Pharmaceuticals about their Phase 3 clinical trial of 150 individuals with mild to moderate COVID-19.
July 22, 2020
A deal securing up to 600 million doses of BNT162(b1,b2) [ BNT162(b1,b2,b3) ] was reached between The U.S. Government, Pfizer, and BioNTech with an assurance that Americans will receive the vaccine for free.
July 22, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) showed an acceptable safety profile as well as elicited both a humoral and cellular immune response in people post-vaccination as demonstrated by a publication in The Lancet. These results support the continued evaluation of this vaccine in Phase III clinical trials.
July 20, 2020
Hospitalized patients who received inhaled Interferon beta-1a* (SNG001) had a 79% lower risk of developing severe disease and were more than twice as likely to recover from COVID-19 as those on placebo in a 101 person Phase II double-blind placebo-controlled trial by Synairgen plc.
July 20, 2020
CanSino’s Ad5-nCoV vaccine was safe and induced significant immune responses in the majority of recipients after a single immunization according to a publication in The Lancet.
July 20, 2020
The Unnamed Inactive Vaccine - Wuhan developed by The Wuhan Institute of Biological Products enters Phase 3 clinical trials in The United Arab Emirates.
July 18, 2020
The Imperial College’s self-amplifying RNA vaccine, LNP-nCoVsaRNA , moves on to Phase 2 clinical trials in The United Kingdom.
July 17, 2020
Over 100 top scientists and Nobel Laureates signed an open letter to the U.S. NIH calling for the production of unattenuated SARS-CoV-2 to test vaccine efficacy in controlled infection trials. The letter also calls for full transparency on vaccine development and trial participant diversity.
July 16, 2020
KBP-COVID-19 , a vaccine generated by using tobacco plants as bioreactors, enters Phase 1/2 clinical trials.
July 16, 2020
A new series of inactive viral vaccines, BBV152A, B, C , developed by Bharat Biotech International Limited enters Phase 1/2 clinical trials in the Republic of India.
July 15, 2020
Interim Phase 1 results for Modern’a mRNA-1273 vaccine were published in the New England Journal of Medicine, indicating that immunization induced anti–SARS-CoV-2 responses in all participants and no trial-limiting safety concerns were identified.
July 14, 2020
Moderna’s mRNA-1273 enter Phase III clinical trials in the United States of America with a targeted enrollment number of 30,000 participants.
July 14, 2020
The mRNA vaccine candidate BNT162(b1,b2,b3) , developed by Biontech Pharmaceuticals and Pfizer has received ‘fast-track’ designation from the U.S. FDA.
July 13, 2020
The anti-interleukin-6 receptor antibody Tocilizumab* was associated with lower mortality in mechanically ventilated patients suffering from COVID-19 in a single-center, small scale study published in the journal Clinical Infectious Disease. This reduction in mortality, however, came with a higher occurrence of bacterial infections.
July 11, 2020
The Unnamed Recombinant Vaccine - Anhui developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 2 clinical trials in China.
July 10, 2020
Johnson & Johnson’s non-replicating Adenvirus type-26 based vaccine, Ad26.COV2.S , enters Phase 1/2 clinical trials in The United States of America and Belgium.
July 9, 2020
A new DNA-based vaccine developed by AnGes Inc., AG0301-COVID19 , starts Phase 1/2 clinical trials in Japan.
July 9, 2020
Immunization with the repurposed vaccine Bacille Calmette-Guerin* was shown to correlate with reduced mortality according to a study published by The Proceedings of the National Academy of Sciences of the United States of America. Clinical trial results will be required to corroborate these findings.
July 9, 2020
the mRNA-based vaccine mRNA-1273 , developed by Moderna, closes enrolment for its Phase 2 SARS-CoV-2 study.
July 8, 2020
The antiviral drug, Favipiravir* , was demonstrated to expedite the recovery of coronavirus patients in a double-blind placebo control clinical trial conducted by the Bangladesh Society of Medicine.
July 6, 2020
Cadila Healthcare Limited’s DNA plasmid vaccine, ZyCoV-D , enters Phase 1/2 clinical trials in The Republic of India.
July 4, 2020
The World Health Organization stops clinical trials involving (Hydroxy)Chloroquine* and combination Lopinavir* / Ritonavir* as the therapies fail to reduce COVID-19 mortality.
July 4, 2020
The inactive vaccine, CoronaVac , developed by Sinovac Biotech starts Phase III clinical trials in Brazil.
July 2, 2020
The anti-IL-6 antibody, Sarilumab* , was not beneficial in COVID-19 patients requiring mechanical ventilation according to Phase 3 clinical trial results released by Sanofi and Regeneron.
July 2, 2020
The mRNA vaccine candidate, BNT162(b1,b2) [ BNT162(b1,b2,b3) ], developed by Biontech Pharmaceuticals and Pfizer was shown to be safe, tolerable, and immunogenic in preprint published results of their Phase 1/2 clinical trials.
July 1, 2020
Testing to resume on the antimalarial drug, (Hydroxy)Chloroquine* , to determine if it can prevent SARS-CoV-2 infection.
June 30, 2020
The DNA plasmid vaccine INO-4800 demonstrates Positive Interim Phase 1 Data according to a press release by Inovio Pharmaceuticals.
June 30, 2020
REGN-COV2 Therapy, Regeneron Pharmaceuticals' anti-spike SARS-CoV-2 monoclonal antibodies enter Phase III clinical trials for prevention of SARS-CoV-2 infection.
June 30, 2020
No clinical benefit was observed from the use of Ritonavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
No clinical benefit was observed from the use of Lopinavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
The Ad5-nCoV vaccine, developed by CanSino Biologics Inc., gets approval for military use in China.
June 29, 2020
Remdesivir* , Gilead Sciences’ treatment found to have worked in COVID-19 clinical trials, will cost U.S. hospitals $3,120 for the typical patient with private insurance.
June 29, 2020
An Unnamed VLP Vaccine produced by Medicago Inc. enters Phase I clinical trials.
June 29, 2020
BBIBP-CorV , the inactive viral vaccine developed by the Beijing Institute of Biological Products and Sinopharm, was found to be safe and able to generate high titers of antibodies among participants in phase I and II clinical trials according to a company press release.
June 28, 2020
DUR-928 , a drug with a novel mechanism of action developed by Durect, enters Phase 2 clinical trials.
June 26, 2020
an mRNA vaccine, CVnCoV , developed by CureVac and Coalition for Epidemic Preparedness Innovations enters Phase 1 Clinical trials in Germany.
June 26, 2020
M5049 , a small molecule that blocks two innate immune sensors that detect single-stranded RNA from viruses, developed by EMD Serono and Merck enters Phase 2 Clinical trials.
June 26, 2020
The DNA plasmid vaccine, INO-4800 , developed by Inovio Pharmaceuticals in collaboration with International Vaccine Institute and Coalition for Epidemic Preparedness Innovations enters Phases 1/2 in the Republic of Korea.
June 25, 2020
GX-19 , a DNA vaccine expressing SARS-CoV-2 S-protein antigen developed by Genexine, Inc., enters Phase 1/2 clinical trials in the Republic of Korea.
June 24, 2020
A new Unnamed Recombinant Vaccine - Anhui developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 1 clinical trials in China.
June 24, 2020
News reports indicate that the Unnamed Inactive Vaccine - Wuhan developed by the Wuhan Institute of Biological Products and Sinopharm induced neutralizing antibodies in all vaccinated individuals, and that Phase III clinical trials will start June 23rd in both China and the United Arab Emirates.
June 23, 2020
AZD1222 (ChAdOx1 nCoV-19) starts Phase 1/2 clinical trials to assess safety, immunogenicity, and efficacy in adults with and without HIV in South Africa. This study is a partnership between the University of Witwatersrand, the University of Oxford, the Medical Research Council of South Africa, and the Bill and Melinda Gates Foundation.
June 23, 2020
Inhaled version of antiviral Remdesivir* to start human clinical trials in August according to Gilead Sciences.
June 22, 2020
The Unnamed Inactive Vaccine - Yunnan being developed by The Chinese Academy of Medical Sciences enters Phase II of clinical trials testing.
June 20, 2020
Gam-COVID-Vac , a new adenoviral-based vaccine developed by Gamaleya Research Institute, starts phase 1/2 clinical trials in Russia.
June 18, 2020
Preliminary results from the Oxford University RECOVERY trial in the United Kingdom indicates that low-dose Dexamethasone* can reduce mortality by approximately one-third in COVID-19 patients on ventilators and by one-fifth of patients on oxygen.
June 16, 2020
A self-amplifying RNA-based vaccine candidate developed by Imperial College London in partnership with Morningside Ventures named CoVac-1
enters Phase 1/2 clinical trials.
June 15, 2020
The U.S. FDA revokes emergency authorization of (Hydroxy)Chloroquine* for treatment of COVID-19 amid growing evidence of ineffectiveness and the possibility of harmful side effects.
June 15, 2020
Preprint article in medRxiv indicates that Lenzilumab was safe and associated with improved clinical outcomes in high-risk COVID-19 patients with severe and critical pneumonia.
June 14, 2020
AstraZeneca has reached an agreement to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222 (ChAdOx1 nCoV-19) , to Germany, France, Italy, and the Netherlands, with deliveries starting by the end of 2020.
June 13, 2020
Sinovac announces no severe adverse events reported and that neutralizing antibodies developed 14 days after the vaccination in its preliminary results of phase 1/2 clinical trial for the Company’s COVID-19 vaccine candidate, CoronaVac .
June 13, 2020
June 12th - A new Unnamed Spike Protein Candidate developed by The University of Queensland enters Phase 1 clinical trials in Australia.
June 12, 2020
Preprint article in medRxiv indicates that the administration of Tocilizumab* is associated with rapid improvement in some clinical indices of those individuals not on ventilation, however, controlled clinical trials are needed to confirm its utility.
June 12, 2020
A novel protein subunit vaccine created by Vaxine and Medytox, COVAX-19 , enters Phase I clinical trials in the US.
June 11, 2020
Moderna moves forward with 100 ug dosage for Phase 3 clinical trial of mRNA-1273 and partners with Lonza to scale up manufacturing potential to generate between 500 million and 1 billion vaccine doses per year.
June 11, 2020
Remdesivir* shows clinical benefit in non-human primates infected with SARS-CoV2, as published in Nature.
June 9, 2020
A publication in the journal Cell indicates that administration of Beijing Institute of Biological Products and Sinopharm’s inactive vaccine, BBIBP-CorV , generates high neutralizing antibody titers and is safe, effective, and stable in numerous animals animal models, including non-human primates.
June 6, 2020
A Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial on (Hydroxy)Chloroquine* indicates no clinical benefit from its use in hospitalized patients with COVID-19.
June 5, 2020
Preprint article in medRxiv indicates that Bacille Calmette-Guerin* vaccination was associated with reduced COVID-19 mortality in level 4:Do Not Travel countries when adjusted for a number of confounding variables.
June 5, 2020
Novavax secures upto $60M from the U.S. Department of Defense to support the production of their NVX-CoV2373 vaccine. The agreement includes a 2020 delivery of 10 million doses for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by the U.S. FDA.
June 4, 2020
The WHO resumes its COVID-19 (Hydroxy)Chloroquine* study after a publication in The Lancet that questioned the safety and efficacy of the drug was retracted. Questions surrounding data analysis and transparency resulted in the retraction of the publication.
June 3, 2020
A new study published in the New England Journal of Medicine indicates that prophylactic (Hydroxy)Chloroquine* did not prevent Covid-19 or confirmed SARS-CoV-2 infection within 4 days After high-risk or moderate-risk exposure.
June 3, 2020
The Brazilian Health Regulatory Agency approves human trials for Oxford University and AstraZeneca's AZD1222 (ChAdOx1 nCoV-19) . 2000 participants will be considered in Brazil through a study carried out by Oxford University and supported by AstraZeneca.
June 2, 2020
A report released indicates that the Phase 3 clinical trials for Moderna’s COVID-19 experimental vaccine, mRNA-1273 , will start in July with the enrollment of 30,000 individuals in a randomized, placebo-controlled trial.
June 2, 2020
Intravenous Immunoglobulin (IVIG; Octagam) therapy sponsored by Octapharma and Sharp HealthCare enters Phase IV clinical trials for COVID-19.
June 2, 2020
A new Unnamed Inactive Vaccine SARS-CoV-2 vaccine being developed by the Chinese Academy of Medical Sciences in collaboration with West China Second University Hospital and Yunnan Center for Disease Control and Prevention enters Phase 1/2.
June 2, 2020
Results released by Gilead indicate that in a Phase III trial, Remdesivir* treatment resulted in significantly greater clinical improvement versus standard of care treatment alone.
June 1, 2020
The immunosuppressive/antiviral Merimepodib* by ViralClear Pharmaceuticals enters Phase II clinical trials against COVID-19.
June 1, 2020
Emergent BioSolutions enters into a $628 million contract with the US government to boost manufacturing capacity for a COVID-19 vaccine.
June 1, 2020
mRNA-1273 , the joint vaccine initiative by Moderna, NIAID, and BARDA, enters Phase 2 clinical trials for COVID-19.
May 28, 2020
The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019 , enters Phase 1 clinical trials against COVID-19.
May 28, 2020
France’s health ministry cancels the usage of (Hydroxy)Chloroquine* as a treatment to patients suffering severe forms of COVID-19.
May 27, 2020
The United Kingdom National Health Service follows suit behind The United States and Japan and authorizes the use of Remdesivir* for people with coronavirus infection after a publication in The New England Journal of Medicine indicates it can cut recovery time by about four days.
May 26, 2020
The World Health Organization suspends testing of (Hydroxy)Chloroquine* as a treatment for coronavirus after publication in The Lancet suggests drug could increase the risk of patients dying from COVID-19.
May 25, 2020
Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).
May 25, 2020
Sinovac Biotech Co. has received $15M in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac .
May 25, 2020
CanSino Biologics’ Ad5-nCoV vaccine starts Phase 1/2 clinical trials in Canada against COVID-19 in collaboration with the Canadian Center for Vaccinology.
May 22, 2020
Phase 1 results for CanSino Biologics’ Ad5-nCoV vaccine published in The Lancet indicate it was tolerable and immunogenic in humans and warrants further clinical trials testing.
May 22, 2020
AstraZeneca/The University of Oxford vaccine AZD1222 (ChAdOx1 nCoV-19) starts Phase 2 / 3 clinical trials for COVID-19.
May 22, 2020
The INOPulse Delivery System by Bellerophon Therapeutics enters Phase 2 clinical trials for COVID-19.
May 22, 2020
AZD1222 (ChAdOx1 nCoV-19) , developed by the University of Oxford and licensed to AstraZeneca secures $1.2 billion backing from U.S Department of Health for accelerated development.
May 21, 2020
Publication in Nature Communications demonstrates robust antibody and cellular immunity elicited by Inovio's INO-4800 vaccine in preclinical models.
May 20, 2020
Inovio Pharmaceuticals press release announces positive interim Phase 1 data for their INO-4800 vaccine.
May 20, 2020
The elastase inhibitor MPH996* starts Phase 2 clinical trials for COVID-19 in Egypt.
May 20, 2020
Inovio Pharmaceutical's INO-4800 vaccine elicits robust immune response in preclinical models as shown in Nature Communications publication.
May 20, 2020
The C3 complement inhibitor AMY-101 sponsored by Amyndas Pharmaceuticals starts Phase 2 clinical trials for severe COVID-19.
May 20, 2020
Atea Pharmaceuticals' AT-527 , a novel modified guanosine nucleotide prodrug, starts Phase 2 for COVID-19.
May 20, 2020
ABX464 , a small molecule inhibitor of the cap binding complex sponsored by Abivax enters Phase 2 / 3 clinical trials for COVID-19.
May 19, 2020
Moderna press release announces positive interim Phase 1 data for its mRNA Vaccine, mRNA-1273 .
May 18, 2020
Health Canada approves human testing for CanSino Biologics's Ad5-nCoV vaccine. Trial will be conducted out of the Canadian Centre for Vaccinology at Dalhousie University.
May 18, 2020
Molnupiravir , an oral nucleoside analog sponored by Ridgeback Biotherapeutics and Merck, enters Phase I clinical trials for COVID-19.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Ravulizumab into Phase 4 clinical trials.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Baricitinib* into Phase 4 clinical trials.
May 18, 2020
Implicit Bioscience and the University of Washington’s anti-CD14 antibody, IC14 , enters Phase 2 clinical trials for COVID-19.
May 18, 2020
The anti-malarial Artemisinin* enters Phase 2 clinical trials for COVID-19.
May 15, 2020
AV-COVID-19 is a new dendritic cell vaccine in Phases 1/2 clinical trials for COVID-19.
May 13, 2020
Ifenprodil , an NDMA inhibitor by Algernon Pharmaceuticals and Novatech starts Phase 2 / 3 clinical trials for COVID-19.
May 11, 2020
The vaccine for tuberculosis, Bacille Calmette-Guerin* is now in consideration for COVID-19. Undergoing clinical Phases 3/4 trials.
April 20, 2020
Subscribe to Updates Enter your email to get alerted with major weekly updates.
Vaccines
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
179
TOTAL
122 in preclinical development
56 in human trials
Vaccine Candidates Development Progress
Vaccine CANDIDATES
Preclinical
122
Phase I
51
Phase II
30
Phase III
15
Phase IV
3
Legend
Completed
In trials
Vaccine CandidatesClick on name for additional information
| ↓/↑ | Name ↓/↑ | Organization ↓/↑ | Technology ↓/↑ | Stage ↓ | Countries ↓/↑ | Clinical Trial # | ||
|---|---|---|---|---|---|---|---|---|
| Multiple Organizations | Repurposed | Phase III/IV | ![Global](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="56" height="56"><rect fill-opacity="0"/></svg>) | NCT04357028 and 2 more | ||||
| Multiple Organizations | Repurposed | Phase III/IV | | NCT04328441 and 25 more | ||||
| Multiple Organizations | Repurposed | Phase III/IV | | NCT04445428 and 1 more | ||||
| Multiple Organizations | Repurposed | Phase III | ![Canada](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="112" height="112"><rect fill-opacity="0"/></svg>) ![United Kingdom](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="97" height="96"><rect fill-opacity="0"/></svg>) | NCT04442048 | ||||
Inmunotek S.L., BioClever 2005 S.L. | Repurposed | Phase III |  | NCT04452643 | ||||
 | Multiple Organizations | RNA-based vaccine | Phase I/II/III | ![United States of America](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="97" height="97"><rect fill-opacity="0"/></svg>) | NCT04283461 and 2 more | |||
| Multiple Organizations | Non-replicating viral vector | Phase I/II/III | ![China](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="96" height="96"><rect fill-opacity="0"/></svg>) | NCT04313127 and 8 more | |||
| Multiple Organizations | Inactivated virus | Phase I/II/III | | NCT04352608 and 6 more | |||
| Multiple Organizations | Inactivated virus | Phase I/II/III | | ChiCTR2000032459 and 3 more | ||||
updated | Multiple Organizations | Inactivated virus | Phase I/II/III | | ChiCTR2000031809 and 3 more | |||
| Multiple Organizations | RNA-based vaccine | Phase I/II/III | | EudraCT 2020-001038-36 and 8 more | ||||
Novavax, Takeda | Protein subunit | Phase I/II/III | | NCT04368988 and 4 more | ||||
updated | Multiple Organizations | Non-replicating viral vector | Phase I/II/III | | NCT04436276 and 5 more | |||
| Multiple Organizations | Non-replicating viral vector | Phase I/II/III | | NCT04324606 and 10 more | |||
| Multiple Organizations | Non-replicating viral vector | Phase I/II/III | ![Russia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="1974" height="1974"><rect fill-opacity="0"/></svg>) | NCT04437875 and 4 more | ||||
Altimmune, Inc. | Repurposed | Phase II | | NCT04442230 | ||||
| Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I/II | | NCT04276896 | |||
| Multiple Organizations | DNA-based | Phase I/II | | NCT04336410 and 1 more | |||
Kentucky BioProcessing, Inc. | Protein subunit | Phase I/II | | NCT04473690 | ||||
Arcturus Therapeutics, Inc., Duke-NUS | RNA-based vaccine | Phase I/II |  | NCT04480957 | ||||
Imperial College London, Morningside Ventures | RNA-based vaccine | Phase I/II | | IRAS-Number: 279315 and 1 more | ||||
CureVac AG, Coalition for Epidemic Preparedness Innovations (CEPI) | RNA-based vaccine | Phase I/II | | NCT04449276 and 1 more | ||||
Sanofi Pasteur, GlaxoSmithKline | Protein subunit | Phase I/II | | NCT04537208 | ||||
AnGes, Inc., Japan Agency for Medical Research and Development | DNA-based | Phase I/II | NCT04463472 and 1 more | |||||
Zydus Cadila, Cadila Healthcare Limited | DNA-based | Phase I/II | CTRI/2020/07/026352 | |||||
Immunitor LLC | Inactivated virus | Phase I/II | | NCT04380532 | ||||
Aivita Biomedical, Inc. | Modified APC | Phase I/II | | NCT04386252 | ||||
| Multiple Organizations | Inactivated virus | Phase I/II | | NCT04412538 and 1 more | ||||
Immunovative Therapies, Ltd., Mirror Biologics, Inc. | Other | Phase I/II | | NCT04441047 | ||||
Genexine, Inc. | DNA-based | Phase I/II | NCT04445389 | |||||
Bharat Biotech International Limited, Indian Council of Medical Research | Inactivated virus | Phase I/II | ![Republic of India](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="2133" height="2134"><rect fill-opacity="0"/></svg>) | NCT04471519 | ||||
| Multiple Organizations | Protein subunit | Phase I/II | | NCT04445194 and 2 more | ||||
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Protein subunit | Phase I/II | | NCT04527575 | ||||
Research Institute for Biological Safety Problems, National Scientific Center for Phthisiopulmonology of the Republic of Kazakhstan | Inactivated virus | Phase I/II | NCT04530357 | |||||
Israel Institute for Biological Research | Replicating viral vector | Phase I/II | NCT04608305 | |||||
| Multiple Organizations | DNA-based | Phase I | | NCT04334980 | |||
| Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I | | NCT04299724 | |||
Medicago Inc. | Virus Like Particle | Phase I | | NCT04450004 | ||||
United Biomedical Inc., Asia, COVAXX | Protein subunit | Phase I | ![Taiwan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="512" height="512"><rect fill-opacity="0"/></svg>) | NCT04545749 | ||||
| Multiple Organizations | Replicating viral vector | Phase I | | NCT04497298 | ||||
Clover Biopharmaceuticals | Protein subunit | Phase I | | NCT04405908 | ||||
| Multiple Organizations | Protein subunit | Phase I | | ACTRN12620000674932 and 1 more | ||||
Vaxart | Non-replicating viral vector | Phase I | | NCT04563702 | ||||
| Multiple Organizations | Protein subunit | Phase I | | NCT04428073 and 1 more | ||||
Medigen Vaccine Biologics Corp. | Protein subunit | Phase I | | NCT04487210 | ||||
| Multiple Organizations | RNA-based vaccine | Phase I | | ChiCTR2000034112 | ||||
Merck Sharp & Dohme Corp. | Replicating viral vector | Phase I | | NCT04498247 | ||||
Adimmune Corporation | Protein subunit | Phase I | | NCT04522089 | ||||
Oklahoma Medical Research Foundation, University of Oklahoma | Repurposed | Phase I | | NCT04523246 | ||||
ReiThera Srl, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani | Non-replicating viral vector | Phase I | NCT04528641 | |||||
University Hospital Tuebingen | Protein subunit | Phase I | | NCT04546841 | ||||
Jiangsu Province Centers for Disease Control and Prevention, West China Hospital | Protein subunit | Phase I | | NCT04530656 and 1 more | ||||
| Multiple Organizations | RNA-based vaccine | Phase I | NCT04566276 | |||||
Entos Pharmaceuticals Inc., Canadian Institutes of Health Research | DNA-based | Phase I | | NCT04591184 | ||||
| Multiple Organizations | Replicating viral vector | Phase I | | NCT04569383 | ||||
ImmunityBio, Inc. | Non-replicating viral vector | Phase I | | NCT04591717 | ||||
Merck Sharp & Dohme Corp. | Replicating viral vector | Phase I | | NCT04569786 | ||||
Fundació Institut Germans Trias i Pujol | Repurposed | Phase N/A | NCT04453488 | |||||
| PittCoVacc | University of Pittsburgh | Protein subunit | Preclinical Phase | | ||||
| DPX-COVID-19 | IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority, Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada | Protein subunit | Preclinical Phase | | ||||
| AdCOVID | Altimmune, University of Alabama at Birmingham | Non-replicating viral vector | Preclinical Phase | | ||||
| CoroFlu | Multiple Organizations | Inactivated virus | Preclinical Phase | | ||||
| +(117) others | - | - | Preclinical Phase | - |
Therapeutic Drugs
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
437
+4
TOTAL
87 in preclinical development
350 in human trials
Drug Candidates Development Progress
Drug CANDIDATES
Preclinical
82
Phase I
114
Phase II
252
Phase III
129
Phase IV
47
Legend
Completed
In trials
Drug CandidatesClick on name for additional information
| ↓/↑ | Name ↓/↑ | Organization ↓/↑ | Technology ↓/↑ | Stage ↓ | Clinical Trial # | ||
|---|---|---|---|---|---|---|---|
Radboud Universit, National University of Ireland, Galway, Ireland | Other | Phase IV | NCT04335786 and 1 more | ||||
Ascletis Pharmaceuticals Co., Ltd., The Ninth Hospital of Nanchang | Antivirals | Phase IV | NCT04291729 | ||||
Mianyang Central Hospital | Antivirals | Phase IV | ChiCTR2000030535 | ||||
| Multiple Organizations | Other | Phase IV | ChiCTR2000029573 and 1 more | ||||
| Multiple Organizations | Other | Phase IV | NCT04286503 | ||||
| Therapeutic Plasma Exchange | Multiple Organizations | Other | Phase IV | NCT04441996 and 3 more | |||
| Bivalirudin | Hamad Medical Corporation | Other | Phase IV | NCT04445935 | |||
| Somatotropin | ClinAmygate | Dormant / Discontinued | Phase IV | x-NCT04532554 | |||
| Multiple Organizations | Antivirals | Phase III/IV | ChiCTR2000029541 and 4 more | |||
| Multiple Organizations | Antibodies | Phase III/IV | NCT04369469 and 2 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04355936 and 9 more | ||||
updated | | Multiple Organizations | Antivirals | Phase II/III/IV | NCT04303299 and 37 more | ||
| Multiple Organizations | Antibodies | Phase II/III/IV | NCT04317092 and 54 more | |||
| Multiple Organizations | Other | Phase II/III/IV | NCT04484493 and 29 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04356833 and 4 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04324021 and 25 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04351347 and 22 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04335032 and 3 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04351724 and 6 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT02735707 and 14 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04321993 and 15 more | ||||
| Multiple Organizations | Other | Phase II/III/IV | NCT04351724 and 2 more | ||||
| Doxycycline* | Multiple Organizations | Other | Phase II/III/IV | NCT04371952 and 12 more | |||
| Sofosbuvir* | Multiple Organizations | Antivirals | Phase II/III/IV | NCT04443725 and 8 more | |||
| Ledipasvir* | Multiple Organizations | Antivirals | Phase II/III/IV | NCT04497649 and 2 more | |||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04261517 and 119 more | |||
updated | | Multiple Organizations | Antivirals | Phase I/II/III/IV | NCT04303299 and 47 more | ||
| Multiple Organizations | Antibodies | Phase I/II/III/IV | NCT04357808 and 13 more | |||
updated | Multiple Organizations | Antibodies | Phase I/II/III/IV | NCT04321421 and 108 more | |||
updated | Multiple Organizations | Antibodies | Phase I/II/III/IV | NCT04261426 and 16 more | |||
| Multiple Organizations | Antivirals | Phase I/II/III/IV | NCT04303299 and 49 more | ||||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04321096 and 12 more | ||||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04320238 and 7 more | ||||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04312009 and 8 more | ||||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04381884 and 43 more | ||||
updated | Multiple Organizations | Other | Phase I/II/III/IV | NCT02735707 and 39 more | |||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04344756 and 47 more | ||||
| N-acetylcysteine | Multiple Organizations | Other | Phase I/II/III/IV | NCT04279197 and 6 more | |||
| Povidone-Iodine | Multiple Organizations | Other | Phase I/II/III/IV | NCT04449965 and 14 more | |||
| Multiple Organizations | Other | Phase I/II/III/IV | NCT04325061 and 17 more | ||||
GlaxoSmithKline | Antibodies | Phase III | NCT04376684 | ||||
| Multiple Organizations | Antivirals | Phase III | NCT04261907 and 1 more | |||
Mesoblast, Inc, Icahn School of Medicine at Mount Sinai | Cell-based therapies | Phase III | NCT04371393 and 2 more | ||||
OncoImmune, Inc. | Other | Phase III | NCT04317040 | ||||
Bellerophon | Device | Phase III | NCT04358588 and 2 more | ||||
| Multiple Organizations | Antivirals | Phase III | ChiCTR2000029541 and 2 more | ||||
Vanda Pharmaceuticals | Other | Phase III | NCT04326426 | ||||
Insmed Inc., University of Dundee | Other | Phase III | EudraCT 2020-001643-13 | ||||
| Pacritinib | CTI Biopharma | Other | Phase III | NCT04404361 | |||
| Multiple Organizations | Other | Phase III | NCT04380727 and 2 more | ||||
Biocad | Antibodies | Phase III | NCT04397562 | ||||
| Prasugrel | Azienda Ospedaliera Universitaria Integrata Verona, University of Milan | Other | Phase III | NCT04445623 | |||
University of Lahore, Bahria International Hospital | Other | Phase III | NCT04468646 | ||||
| Rosuvastatin* | Yale University | Other | Phase III | NCT04472611 | |||
| XC221 | RSV Therapeutics LLC | Antivirals | Phase III | NCT04487574 | |||
| Broncho-Vaxom | Multiple Organizations | Other | Phase III | NCT04496245 | |||
| Bucillamine | Revive Therapeutics, Ltd. | Other | Phase III | NCT04504734 | |||
| Losmapimod | Fulcrum Therapeutics | Other | Phase III | NCT04511819 | |||
| Edoxaban* | University Hospital Inselspital, Berne, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Other | Phase III | NCT04516941 | |||
| Brexanolone | Sage Therapeutics | Other | Phase III | NCT04537806 | |||
| Nintedanib | Assistance Publique - Hôpitaux de Paris, Boehringer Ingelheim | Other | Phase III | NCT04541680 | |||
| NA-831* | NeuroActiva, Inc., Biomed Industries, Inc. | Other | Phase III | NCT04540185 | |||
| Nicotine | Assistance Publique - Hôpitaux de Paris | Other | Phase III | NCT04583410 and 1 more | |||
new | Lidocaine | Multiple Organizations | Other | Phase III | NCT04609865 | ||
University of Alabama at Birmingham | Other | Phase II/III | NCT04338126 and 2 more | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04351152 and 2 more | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04275414 and 3 more | |||
| Multiple Organizations | Antibodies | Phase II/III | NCT04322188 and 3 more | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04288713 and 3 more | ||||
Swedish Orphan Biovitrum | Antibodies | Phase II/III | NCT04324021 | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04362813 and 4 more | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04333420 | ||||
| Multiple Organizations | Antivirals | Phase II/III | ChiCTR2000029468 and 4 more | ||||
| VIR-7831 | Vir Biotechnology, Inc., GlaxoSmithKline | Antibodies | Phase II/III | NCT04545060 | |||
Athersys, Inc. | Cell-based therapies | Phase II/III | NCT04367077 | ||||
Algernon Pharmaceuticals, Novotech | Other | Phase II/III | NCT04382924 | ||||
| Multiple Organizations | Other | Phase II/III | NCT04352400 and 2 more | ||||
| Multiple Organizations | Other | Phase II/III | NCT04350320 and 19 more | ||||
Karyopharm Therapeutics, Peter MacCallum Cancer Centre, Australia | Other | Phase II/III | NCT04355676 and 3 more | ||||
Biohaven Pharmaceuticals, Inc. | Other | Phase II/III | NCT04346615 | ||||
| Multiple Organizations | Other | Phase II/III | NCT04350593 and 1 more | ||||
| Multiple Organizations | Other | Phase II/III | NCT04346147 and 4 more | ||||
| Multiple Organizations | Antivirals | Phase II/III | NCT04324489 and 4 more | ||||
| Dipyridamole | Multiple Organizations | Other | Phase II/III | NCT04391179 and 3 more | |||
Abivax S.A. | Other | Phase II/III | NCT04393038 | ||||
Chimerix | Other | Phase II/III | NCT04389840 | ||||
Cambridge University Hospitals NHS Foundation Trust, Evelo Biosciences, Inc. | Other | Phase II/III | NCT04393246 and 1 more | ||||
| Multiple Organizations | Antibodies | Phase II/III | NCT04397497 and 4 more | ||||
| Multiple Organizations | Other | Phase II/III | NCT04331470 and 2 more | ||||
| Secukinumab | Assistance Publique - Hôpitaux de Paris, Lomonosov Moscow State University Medical Research and Educational Center | Antibodies | Phase II/III | EudraCT 2020-001246-18 and 1 more | |||
Restorbio Inc., National Institute on Aging | Other | Phase II/III | NCT04409327 and 1 more | ||||
Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge | Other | Phase II/III | NCT04341038 and 1 more | ||||
| Multiple Organizations | Device | Phase II/III | NCT04409886 and 3 more | ||||
| Opaganib | RedHill Biopharma Limited, Shaare Zedek Medical Center | Other | Phase II/III | NCT04414618 and 3 more | |||
| Lactoferrin | Multiple Organizations | Other | Phase II/III | NCT04421534 and 4 more | |||
| Multiple Organizations | Antibodies | Phase II/III | NCT04381052 and 5 more | ||||
| Ambrisentan* | Cambridge University Hospitals NHS Foundation Trust | Other | Phase II/III | NCT04393246 | |||
| PTC299 | PTC Therapeutics | Other | Phase II/III | NCT04439071 | |||
| Daclatasvir* | Multiple Organizations | Antivirals | Phase II/III | NCT04443726 and 5 more | |||
| BDB-001 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Defengrui Biotechnology Co. Ltd | Other | Phase II/III | NCT04449588 | |||
| Olokizumab | Multiple Organizations | Antibodies | Phase II/III | NCT04380519 and 1 more | |||
| NA-831* | NeuroActiva, Inc. | Other | Phase II/III | NCT04452565 and 1 more | |||
| RPH-104 | Multiple Organizations | Other | Phase II/III | NCT04380519 | |||
| Atazanavir* | Multiple Organizations | Antivirals | Phase II/III | NCT04452566 and 2 more | |||
| RESP301 | Thirty Respiratory Limited | Other | Phase II/III | NCT04460183 | |||
| Acetylsalicylic acid | Multiple Organizations | Other | Phase II/III | NCT04368377 and 8 more | |||
| Atorvastatin | Multiple Organizations | Other | Phase II/III | NCT04380402 and 3 more | |||
| BIO101 | Biophytis | Other | Phase II/III | NCT04472728 | |||
| TD139 | University of Edinburgh, University of Oxford | Other | Phase II/III | NCT04473053 | |||
| Melatonin | Multiple Organizations | Other | Phase II/III | NCT04474483 and 2 more | |||
| Itolizumab | Biocon Limited, Equillium | Antibodies | Phase II/III | NCT04475588 and 1 more | |||
| Apremilast* | QuantumLeap Healthcare Collaborative, Amgen | Other | Phase II/III | NCT04488083 and 1 more | |||
| INM005 | Inmunova S.A. | Antibodies | Phase II/III | NCT04494984 | |||
| Bardoxolone methyl | NYU Langone Health, Reata Pharmaceuticals, Inc. | Other | Phase II/III | NCT04494646 | |||
| Bicalutamide | University of Florida, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Other | Phase II/III | NCT04509999 and 1 more | |||
| Metformin* | University of Minnesota, AgelessRx | Other | Phase II/III | NCT04510194 and 1 more | |||
| IMU-838* | Multiple Organizations | Other | Phase II/III | NCT04516915 and 1 more | |||
| Triazavirin | Multiple Organizations | Antivirals | Phase II/III | NCT04581915 | |||
| Furosemide | Queen's University, University Health Network, Toronto | Other | Phase II/III | NCT04588792 | |||
updated | | Multiple Organizations | Antivirals | Phase I/II/III | NCT04292730 and 34 more | ||
| Multiple Organizations | Other | Phase I/II/III | NCT04268537 and 4 more | ||||
Tang-Du Hospital, Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Antibodies | Phase I/II/III | NCT04275245 and 1 more | ||||
| Multiple Organizations | Antivirals | Phase I/II/III | NCT04356677 and 8 more | ||||
| Multiple Organizations | Other | Phase I/II/III | ChiCTR2000029580 and 20 more | ||||
| Multiple Organizations | Other | Phase I/II/III | NCT04305457 and 17 more | ||||
| Multiple Organizations | Other | Phase I/II/III | NCT04311697 and 3 more | ||||
| Multiple Organizations | Other | Phase I/II/III | NCT04345419 and 10 more | ||||
updated | Multiple Organizations | Other | Phase I/II/III | NCT04343768 and 8 more | |||
| Multiple Organizations | Antivirals | Phase I/II/III | NCT04392219 and 4 more | ||||
| Multiple Organizations | Other | Phase I/II/III | NCT04332666 and 3 more | ||||
| Multiple Organizations | Other | Phase I/II/III | EudraCT 2020-001492-33 and 10 more | ||||
| Multiple Organizations | Antibodies | Phase I/II/III | NCT04411628 and 5 more | ||||
updated | REGN-COV2 | Regeneron Pharmaceuticals | Antibodies | Phase I/II/III | NCT04425629 and 4 more | ||
| CT-P59 | Celltrion | Antibodies | Phase I/II/III | NCT04593641 and 1 more | |||
Washington University School of Medicine | Other | Phase II | NCT04342663 | ||||
| Multiple Organizations | Other | Phase II | NCT04387240 and 3 more | ||||
| Multiple Organizations | Antibodies | Phase II | NCT04268537 and 8 more | ||||
CytoDyn | Antibodies | Phase II | NCT04343651 and 2 more | ||||
Eli Lilly and Company | Antibodies | Phase II | NCT04342897 | ||||
Bukwang Pharmaceutical | Antivirals | Phase II | NCT04347915 | ||||
| Autologous Adipose-derived Stem Cells | Celltex Therapeutics Corporation | Cell-based therapies | Phase II | NCT04428801 | |||
Apeiron Biologics | Other | Phase II | NCT04335136 | ||||
The First Affiliated Hospital of Fujian Medical University, Novartis | Other | Phase II | NCT04280588 | ||||
NYU Langone Health | Other | Phase II | NCT04365699 | ||||
BioAegis Therapeutics Inc. | Other | Phase II | NCT04358406 | ||||
Medical University of Vienna, Apeptico | Other | Phase II | EudraCT 2020-001244-26 | ||||
Pulmotect, Inc. | Other | Phase II | NCT04312997 and 1 more | ||||
| Multiple Organizations | Other | Phase II | NCT04332042 and 3 more | ||||
Laurent Pharmaceuticals | Other | Phase II | NCT04417257 | ||||
Blade Therapeutics | Other | Phase II | NCT04334460 | ||||
CalciMedica, Inc. | Other | Phase II | NCT04345614 | ||||
Can-Fite BioPharma | Other | Phase II | NCT04333472 | ||||
4D pharma plc | Other | Phase II | NCT04363372 | ||||
aTyr Pharma, Inc. | Other | Phase II | NCT04412668 | ||||
University Hospital, Basel, Switzerland, Pharming Technologies B.V. | Other | Phase II | NCT04414631 and 2 more | ||||
| Multiple Organizations | Antibodies | Phase II | NCT04371367 and 1 more | ||||
Arch Biopartners | Other | Phase II | |||||
Kinevant Sciences GmbH, Roivant Sciences, Inc. | Antibodies | Phase II | NCT04351243 | ||||
Implicit Bioscience, University of Washington | Antibodies | Phase II | NCT04346277 and 1 more | ||||
| Multiple Organizations | Other | Phase II | NCT04331899 and 4 more | ||||
BerGenBio, University Hospital Southampton NHS Foundation Trust | Other | Phase II | EudraCT 2020-001736-95 | ||||
University Hospital Southampton NHS Foundation Trust | Antibodies | Phase II | EudraCT 2020-001736-95 | ||||
| Multiple Organizations | Other | Phase II | NCT04382755 and 1 more | ||||
| AT-527 | Atea Pharmaceuticals, Inc. | Antivirals | Phase II | NCT04396106 | |||
| AMY-101 | Amyndas Pharmaceuticals S.A. | Other | Phase II | NCT04395456 | |||
Centre Leon Berard | Other | Phase II | x-NCT04333914 | ||||
Beyond Air Ltd | Device | Phase II | NCT04397692 and 2 more | ||||
| Multiple Organizations | Other | Phase II | NCT04405102 | ||||
ViralClear Pharmaceuticals, Inc. | Antivirals | Phase II | NCT04410354 | ||||
GeneOne Life Science, Inc. | Other | Phase II | NCT04408183 | ||||
CSL Behring | Antibodies | Phase II | NCT04409509 | ||||
| CERC-002 | Aevi Genomic Medicine, LLC, Cerecor Inc | Other | Phase II | NCT04412057 | |||
| Axatilimab | Syndax Pharmaceuticals | Antibodies | Phase II | x-NCT04415073 | |||
| Prostacyclin | Multiple Organizations | Other | Phase II | NCT04420741 and 2 more | |||
Assistance Publique - Hôpitaux de Paris, Iltoo Pharma | Other | Phase II | NCT04357444 | ||||
| Infliximab | Multiple Organizations | Antibodies | Phase II | NCT04425538 and 1 more | |||
| Nangibotide | Inotrem | Other | Phase II | NCT04429334 | |||
| Ibudilast | MediciNova | Other | Phase II | NCT04429555 | |||
| Pamrevlumab | FibroGen | Antibodies | Phase II | NCT04432298 | |||
| PB1046 | PhaseBio Pharmaceuticals Inc. | Other | Phase II | NCT04433546 | |||
| Crizanlizumab | Multiple Organizations | Antibodies | Phase II | NCT04435184 | |||
| Abivertinib Maleate | Sorrento Therapeutics, Inc. | Other | Phase II | NCT04440007 and 1 more | |||
| Ibrutinib | Multiple Organizations | Other | Phase II | NCT04375397 and 1 more | |||
| LAM-002A | AI Therapeutics, Inc., Yale University | Other | Phase II | NCT04446377 | |||
| DUR-928 | Durect | Other | Phase II | NCT04447404 | |||
| M5049 | Multiple Organizations | Other | Phase II | NCT04448756 | |||
| C21 | Vicore Pharma AB, Orphan Reach | Other | Phase II | NCT04452435 | |||
| XAV-19 | Multiple Organizations | Antibodies | Phase II | NCT04453384 | |||
| Enzalutamide | Multiple Organizations | Other | Phase II | NCT04456049 and 1 more | |||
| Atovaquone | University of Texas Southwestern Medical Center | Other | Phase II | NCT04456153 | |||
| ANG-3777 | Angion Biomedica Corp, CTI Clinical Trial and Consulting Services | Other | Phase II | NCT04459676 | |||
| OP-101 | Orpheris, Inc. | Other | Phase II | NCT04458298 | |||
| Monalizumab | Centre Leon Berard | Antibodies | Phase II | x-NCT04333914 | |||
| Desidustat | Cadila Healthcare Limited | Other | Phase II | NCT04463602 | |||
| Clofazimine | The University of Hong Kong | Other | Phase II | NCT04465695 | |||
| Ramelteon | Associação Fundo de Incentivo à Pesquisa | Other | Phase II | NCT04470297 | |||
| Trimethoprim* | Multiple Organizations | Other | Phase II | NCT04470531 and 1 more | |||
| Sulfamethoxazole* | Multiple Organizations | Other | Phase II | NCT04470531 and 1 more | |||
| Nelfinavir* | Tanta University | Antivirals | Phase II | NCT04471662 | |||
| Abatacept | Multiple Organizations | Other | Phase II | NCT04472494 and 2 more | |||
| Pyronaridine* | Shin Poong Pharmaceutical Co. Ltd., Medicines for Malaria Venture | Other | Phase II | NCT04475107 and 1 more | |||
| Vadadustat | The University of Texas Health Science Center, Houston, Akebia Therapeutics Inc. | Other | Phase II | NCT04478071 | |||
| ATI-450 | University of Kansas Medical Center | Other | Phase II | NCT04481685 | |||
| Decitabine | Johns Hopkins University | Other | Phase II | NCT04482621 | |||
| Genistein | Multiple Organizations | Other | Phase II | NCT04482595 | |||
| Ebselen | Sound Pharmaceuticals, Incorporated | Other | Phase II | NCT04483973 and 1 more | |||
| Disulfiram | Multiple Organizations | Other | Phase II | NCT04485130 and 1 more | |||
| Cenicriviroc* | Multiple Organizations | Antivirals | Phase II | NCT04488081 and 2 more | |||
| Duvelisib | Multiple Organizations | Other | Phase II | NCT04372602 and 1 more | |||
| Razuprotafib* | Multiple Organizations | Other | Phase II | NCT04488082 and 1 more | |||
| Icatibant* | QuantumLeap Healthcare Collaborative | Other | Phase II | NCT04488081 | |||
| DB-001 | Direct Biologics, LLC | Other | Phase II | NCT04493242 | |||
| F-652 | Generon (Shanghai) Corporation Ltd. | Antibodies | Phase II | NCT04498377 | |||
| EC-18 | Enzychem Lifesciences Corporation | Other | Phase II | NCT04500132 and 1 more | |||
| Poractant alfa | Chiesi Farmaceutici S.p.A., Versailles Hospital | Other | Phase II | NCT04502433 and 1 more | |||
| DFV890 | Novartis Pharmaceuticals | Other | Phase II | NCT04382053 and 1 more | |||
| AZD1656 | St George Street Capital | Other | Phase II | NCT04516759 | |||
| CSL324 | CSL Behring | Antibodies | Phase II | NCT04519424 | |||
| Thimerosal | Multiple Organizations | Other | Phase II | NCT04522830 | |||
| Antroquinonol | Golden Biotechnology Corporation | Other | Phase II | NCT04523181 | |||
| Ensifentrine | Verona Pharma Inc | Other | Phase II | NCT04527471 | |||
| Tafenoquine | 60 Degrees Pharmaceuticals LLC, Peachtree BioResearch Solutions Inc. | Other | Phase II | NCT04533347 | |||
| Asunercept | Apogenix AG | Other | Phase II | NCT04535674 | |||
| Fisetin | Mayo Clinic, National Institute on Aging | Other | Phase II | NCT04537299 and 1 more | |||
| Dapansutrile | Olatec Therapeutics LLC, CTI Clinical Trial and Consulting Services | Other | Phase II | NCT04540120 | |||
| ISIS 721744 | Multiple Organizations | Other | Phase II | NCT04549922 | |||
| BGB-DXP593 | BeiGene | Antibodies | Phase II | NCT04551898 | |||
| Avasopasem Manganese | Galera Therapeutics, Inc. | Other | Phase II | NCT04555096 | |||
| PLN-74809 | Pliant Therapeutics, Inc. | Other | Phase II | NCT04565249 | |||
| NuSepin | Shaperon | Other | Phase II | NCT04565379 | |||
| EG-HPCP-03a | Evergreen Therapeutics, Inc. | Other | Phase II | NCT04561180 | |||
| PF-06650833 | Yale University, Pfizer | Other | Phase II | NCT04575610 | |||
| Trimodulin | Biotest | Antibodies | Phase II | NCT04576728 | |||
| Risankizumab | National Institute of Allergy and Infectious Diseases | Antibodies | Phase II | NCT04583956 | |||
| Senicapoc | Multiple Organizations | Other | Phase II | NCT04594668 | |||
| Adenosine | University of Florida | Other | Phase II | NCT04588441 | |||
| GLS-1027 | GeneOne Life Science, Inc. | Other | Phase II | NCT04590547 | |||
| Pirfenidone | Institut d'Investigació Biomèdica de Bellvitge | Other | Phase II | NCT04607928 | |||
| Alisporivir | Assistance Publique - Hôpitaux de Paris, Debiopharm International SA | Other | Phase II | NCT04608214 | |||
| BI 764198 | Boehringer Ingelheim | Other | Phase II | NCT04604184 | |||
| Naltrexone* | AgelessRx | Other | Phase II | NCT04604678 and 1 more | |||
| Mesenchymal Stem Cell Exosomes | Clinics of the Federal State Budgetary Educational Institution SSMU, Samara Regional Clinical Hospital V.D. Seredavin | Cell-based therapies | Phase II | NCT04602442 | |||
new | FX06 | Assistance Publique - Hôpitaux de Paris | Other | Phase II | NCT04618042 | ||
new | Semaglutide | Multiple Organizations | Other | Phase II | NCT04615871 | ||
I-Mab Biopharma Co. Ltd. | Antibodies | Phase I/II | NCT04341116 | ||||
| Recombinant ACE2 | Kafrelsheikh University, Apeiron Biologics | Other | Phase I/II | NCT04382950 and 3 more | |||
| Multiple Organizations | Cell-based therapies | Phase I/II | NCT04365101 | ||||
| Natural Killer Cell-based therapy | Multiple Organizations | Cell-based therapies | Phase I/II | NCT04578210 | |||
| Astrostem-V | Naturecell | Cell-based therapies | Phase I/II | NCT04527224 | |||
| Multiple Organizations | Other | Phase I/II | NCT04346199 and 4 more | ||||
Chongqing Public Health Medical Center, Chongqing Sidemu Biotechnology Technology Co.,Ltd. | Cell-based therapies | Phase I/II | NCT04324996 | ||||
Roswell Park Cancer Institute, National Cancer Institute (NCI) | RNA-based treatments | Phase I/II | NCT04379518 | ||||
updated | Multiple Organizations | Cell-based therapies | Phase I/II | ChiCTR2000029990 and 41 more | |||
| Multiple Organizations | Other | Phase I/II | NCT04396067 and 1 more | ||||
| Multiple Organizations | Cell-based therapies | Phase I/II | NCT04344548 and 1 more | ||||
| Multiple Organizations | Other | Phase I/II | NCT04361214 and 1 more | ||||
| Ulinastatin | Stanford University | Other | Phase I/II | NCT04393311 | |||
| Multiple Organizations | Cell-based therapies | Phase I/II | NCT04401410 and 2 more | ||||
Apellis Pharmaceuticals, Inc. | Other | Phase I/II | NCT04402060 | ||||
Theravance Biopharma | Other | Phase I/II | EudraCT 2020-001807-18 and 2 more | ||||
| Multiple Organizations | Other | Phase I/II | NCT04407689 and 5 more | ||||
| TL-895 | Telios Pharma, Inc. | Other | Phase I/II | NCT04419623 | |||
| Lanadelumab | Multiple Organizations | Antibodies | Phase I/II | NCT04422509 and 1 more | |||
| Brequinar | Clear Creek Bio, Inc. | Other | Phase I/II | NCT04425252 and 1 more | |||
| Radiation Therapy | Multiple Organizations | Other | Phase I/II | NCT04427566 and 14 more | |||
| CAStem | Chinese Academy of Sciences, Beijing YouAn Hospital | Cell-based therapies | Phase I/II | NCT04331613 | |||
| Pentoxifylline | Sadat City University | Other | Phase I/II | NCT04433988 | |||
| Maraviroc* | Multiple Organizations | Other | Phase I/II | NCT04435522 and 2 more | |||
| Tramadol | Tanta University | Other | Phase I/II | NCT04454307 | |||
| Rapamycin | Multiple Organizations | Other | Phase I/II | NCT04461340 and 3 more | |||
| Autologous Non-Hematopoietic Peripheral Blood Stem Cells | Abu Dhabi Stem Cells Center | Cell-based therapies | Phase I/II | NCT04473170 | |||
| RAPA-501-Allo cells | Rapa Therapeutics LLC, Hackensack Meridian Health | Cell-based therapies | Phase I/II | NCT04482699 | |||
| Sildenafil | Multiple Organizations | Other | Phase I/II | NCT04489446 and 1 more | |||
| Alpha-1 antitrypsin | Multiple Organizations | Other | Phase I/II | NCT04495101 and 2 more | |||
| Allocetra-OTS | Multiple Organizations | Cell-based therapies | Phase I/II | NCT04513470 and 1 more | |||
updated | Anti-SARS-CoV-2 Equine Immunoglobulin | Multiple Organizations | Antibodies | Phase I/II | NCT04514302 and 2 more | ||
| Crocetin | Diffusion Pharmaceuticals Inc. | Other | Phase I/II | NCT04573322 | |||
| Fostamatinib | Multiple Organizations | Other | Phase I/II | NCT04579393 and 1 more | |||
| COVI-AMG | Sorrento Therapeutics, Inc. | Antibodies | Phase I/II | NCT04584697 | |||
| NGM621 | NGM Biopharmaceuticals, Inc | Antibodies | Phase I/II | NCT04582318 | |||
| COVID19-0001-USR | United Medical Specialties | Other | Phase I/II | NCT04595136 | |||
| Regadenoson | University of Maryland, Baltimore | Other | Phase I/II | NCT04606069 | |||
new | Methotrexate | University of Sao Paulo General Hospital, Hospital Santa Marcelina | Other | Phase I/II | NCT04610567 | ||
BioCryst Pharmaceuricals | Antivirals | Phase I | NCT03891420 | ||||
| SAB-185 | Multiple Organizations | Antibodies | Phase I | NCT04468958 and 1 more | |||
PharmaMar, Apices Soluciones S.L. | Other | Phase I | NCT04382066 | ||||
ImmunityBio, Inc. | Other | Phase I | NCT04385849 | ||||
| Idronoxil | Noxopharm Limited | Other | Phase I | NCT04555213 | |||
Millennium Pharmaceuticals, Inc. | Other | Phase I | NCT03648372 | ||||
| JS016 | Shanghai Junshi Bioscience Co., Ltd. | Antibodies | Phase I | NCT04441918 | |||
Masonic Cancer Center, University of Minnesota | Cell-based therapies | Phase I | NCT04363346 | ||||
Xinxiang Medical University, First Affiliated Hospital of Xinjiang Medical University | Cell-based therapies | Phase I | NCT04280224 | ||||
| TRV027 | Imperial College London | Other | Phase I | NCT04419610 | |||
| TY027 | Tychan Pte Ltd. | Antibodies | Phase I | NCT04429529 | |||
| MK-5475 | Merck Sharp & Dohme Corp. | Other | Phase I | X-NCT04425733 | |||
| BAT2020 | Bio-Thera Solutions | Other | Phase I | NCT04432766 | |||
| COVI-Guard | Sorrento Therapeutics, Inc. | Antibodies | Phase I | NCT04454398 | |||
| Ampion | Ampio Pharmaceuticals. Inc. | Other | Phase I | NCT04456452 and 1 more | |||
| CPI-006 | Corvus Pharmaceuticals, Inc. | Antibodies | Phase I | NCT04464395 | |||
| TAK-671 | Takeda | Other | Phase I | NCT04464460 | |||
| CK0802 | Cellenkos, Inc. | Cell-based therapies | Phase I | NCT04468971 | |||
| SAR443122 | Sanofi | Other | Phase I | NCT04469621 | |||
| BRII-196 | Brii Biosciences Limited, TSB Therapeutics (Beijing) CO.LTD | Antibodies | Phase I | NCT04479631 | |||
| SCTA01 | Sinocelltech Ltd. | Antibodies | Phase I | NCT04483375 | |||
| PSC-04 | Multiple Organizations | Cell-based therapies | Phase I | NCT04486001 | |||
| NT-17 | NeoImmuneTech | Other | Phase I | NCT04501796 | |||
| AZD7442 | AstraZeneca, Parexel | Antibodies | Phase I | NCT04507256 | |||
| CT-P59 | Celltrion | Antibodies | Phase I | NCT04525079 | |||
| MPT0B640 | Joseah Bio | Other | Phase I | NCT04526717 | |||
| VIB7734 | Viela Bio | Antibodies | Phase I | NCT04526912 | |||
| Defibrotide | Jazz Pharmaceuticals | Other | Phase I | NCT04530604 | |||
| S-nitrosylation | Case Western Reserve University, University Hospitals Cleveland Medical Center | Other | Phase I | NCT04528771 | |||
| PF-07304814 | Pfizer | Antivirals | Phase I | NCT04535167 | |||
| BGB DXP593 | BeiGene | Antibodies | Phase I | NCT04532294 | |||
| MW33 | Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai Public Health Clinical Center | Antibodies | Phase I | NCT04533048 | |||
| IN01 | Multiple Organizations | Other | Phase I | NCT04537130 | |||
| HLX70 | Multiple Organizations | Antibodies | Phase I | NCT04561076 | |||
| anti-SARS-CoV-2 IgY | Stanford University | Antibodies | Phase I | NCT04567810 | |||
| Fluoxetine | Milton S. Hershey Medical Center | Other | Phase I | NCT04570449 | |||
| RLS-0071 | ReAlta Life Sciences, Inc. | Other | Phase I | NCT04574869 | |||
| HLX71 | Hengenix Biotech Inc | Other | Phase I | NCT04583228 | |||
| HFB30132A | HiFiBiO Therapeutics | Antibodies | Phase I | NCT04590430 | |||
| ADM03820 | Ology Bioservices, Enabling Biotechnologies | Antibodies | Phase I | NCT04592549 | |||
Roche, The First Affiliated Hospital of Zhejiang University Medical School | Antivirals | Phase N/A | ChiCTR2000029544 and 1 more | ||||
He'nan Sincere Biotechnology Co., Ltd, | Antivirals | Phase N/A | ChiCTR2000030487 and 3 more | ||||
Capricor Inc. | Cell-based therapies | Phase N/A | NCT04338347 | ||||
| Multiple Organizations | Device | Phase N/A | NCT04324528 and 3 more | ||||
Marker Therapeutics AG | Device | Phase N/A | NCT04358003 | ||||
| Seraph-100 Microbind Affinity Blood Filter | Multiple Organizations | Device | Phase N/A | NCT04413955 and 2 more | |||
| Continuous Positive Airway Pressure Helmet | Multiple Organizations | Device | Phase N/A | NCT04395807 and 2 more | |||
| KB109* | Kaleido Biosciences | Other | Phase N/A | NCT04414124 and 1 more | |||
| Vielight RX Plus | Vielight Inc. | Device | Phase N/A | NCT04418505 | |||
| ensoETM | Washington University School of Medicine | Device | Phase N/A | NCT04426344 | |||
| High Flow Nasal Cannula Device | Multiple Organizations | Device | Phase N/A | NCT04424836 and 2 more | |||
| VibroLUNG | Astana Medical University | Device | Phase N/A | NCT04435353 | |||
| Dutasteride | Applied Biology, Inc. | Other | Phase N/A | NCT04446429 | |||
| MakAir | Nantes University Hospital | Device | Phase N/A | NCT04475185 | |||
| oXiris Hemofilter | Zan Mitrev Clinic | Device | Phase N/A | NCT04478539 | |||
| Platelet Lysate | Regenexx, LLC | Other | Phase N/A | NCT04487691 | |||
| Auricular Percutaneous Neurostimulation | Olive View-UCLA Education & Research Institute | Device | Phase N/A | NCT04514627 | |||
| Fenofibrate | University of Pennsylvania, University of Arizona | Other | Phase N/A | NCT04517396 | |||
| EmitBioâ„¢ RD19 | Multiple Organizations | Device | Phase N/A | NCT04525976 | |||
| Aprotinin | Aviron LLC | Other | Phase N/A | NCT04527133 | |||
| Positive Expiratory Pressure Flute | Bispebjerg Hospital, Hvidovre University Hospital | Device | Phase N/A | NCT04530435 | |||
| C2Rx | SeaStar Medical | Device | Phase N/A | NCT04537975 | |||
| Azoximer bromide | NPO Petrovax | Antivirals | Phase N/A | NCT04542226 | |||
| Estrogen Therapy | CMN "20 de Noviembre" | Other | Phase N/A | NCT04539626 | |||
| Surfactant | Biosurf LLC. | Other | Phase N/A | NCT04568018 | |||
| UV Light Device | Cedars-Sinai Medical Center, Aytu BioScience, Inc. | Device | Phase N/A | NCT04572399 | |||
| REGN3048-3051 | Regeneron | Antibodies | Preclinical Phase | ||||
| Polyclonal hyperimmune globulin | Multiple Organizations | Antibodies | Preclinical Phase | ||||
| VIR-7832 | Multiple Organizations | Antibodies | Preclinical Phase | ||||
updated | PLX-PAD | Pluristem Ltd. | Cell-based therapies | Preclinical Phase | NCT04389450 and 1 more | ||
| AmnioBoost | Lattice Biologics* | Cell-based therapies | Preclinical Phase | ||||
| SNG001 | Synairgen, University of Southampton | Other | Preclinical Phase | ||||
| Brilacidin | Innovation Pharmaceuticals | Other | Preclinical Phase | ||||
| DIBI | Chelation Partners | Other | Preclinical Phase | ||||
| GP1681 | Quotient Sciences, CytoAgents | Other | Preclinical Phase | ||||
| Multiple Organizations | Antivirals | Phase I/IV | NCT04252885 and 6 more | ||||
| Multiple Organizations | Antivirals | Phase I/III/IV | NCT04303299 and 8 more | ||||
| Multiple Organizations | Other | Phase II/IV | NCT04326920 and 4 more | ||||
| Multiple Organizations | Other | Phase I/III/IV | NCT04370262 and 3 more | ||||
| Multiple Organizations | Other | Phase I/II/IV | NCT04412785 and 6 more | ||||
| Bromhexine* | Multiple Organizations | Other | Phase I/III/IV | NCT04355026 and 4 more | |||
| Chlorhexidine | NYU Langone Health, Ohio State University | Other | Phase II/IV | NCT04344236 and 1 more | |||
| +(73) others | - | - | Preclinical Phase | - |
* May be used in combination with other therapeutics. Clinical trials mentioned contain this included drug in the regimen.
Phase N/A: Not Applicable, describes trials without FDA-defined phases, including trials of devices or behavioral interventions.
Phase N/A: Not Applicable, describes trials without FDA-defined phases, including trials of devices or behavioral interventions.
Subscribe to Updates Enter your email to get alerted with major weekly updates.
We appreciate you browsing our vaccine tracker! If you'd like to give us any feedback on the content, data, or suggestions for improvement, please email us your feedback at vaccinetracker@biorender.com.
COVID-19 Vaccine Tracker is powered by BioRender.
BioRender is an online tool for creating professional and beautiful scientific figures.
Sign Up Free
FAQ
What is the science behind COVID-19?
COVID-19 is a new infectious disease caused by the coronavirus strain SARS-CoV-2. Disease manifestations usually occur in the lungs of infected individuals, however, it has been reported that other parts of the body can be impacted as well. Upon infection, there is an asymptomatic period of variable length in which individuals can spread the virus without even knowing it. Some people may clear the virus without ever showing symptoms at all, while other individuals may start to experience some or all of the following symptoms: fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, and loss of taste and/or smell. From here, individuals generally recover from the infection with or without supportive care, but there is a subset of infected individuals that may succumb to the illness and die.
Although the science of SARS-CoV-2 is evolving every day, this virus is thought to be more infectious and deadly than the seasonal strain of flu, and more infectious but less deadly than the recently publicized Middle Eastern Respiratory Syndrome (MERS) coronavirus. There are currently no vaccines or therapeutics available to prevent or treat COVID-19.
What are the differences between vaccines and therapeutic drugs?
Vaccines are biological preparations that, when administered to an individual, provide protection from a specific entity, such as a virus or bacteria. Vaccines prime the immune system and create a form of memory, so that you can respond faster and with greater magnitude against a threat than if you were encountering it for the first time. Vaccines can be composed of proteins, nucleic acids (DNA and RNA), or even entire organisms and their potency can be boosted by chemicals known as adjuvants. Vaccines are most commonly used prophylactically (to prevent an infection or disease).
Therapeutic Drugs are any molecules that are used to diagnose, treat or prevent a disease. Unlike vaccines, therapeutic drugs directly affect the disease in question or modulate the immune system to help deal with the disease, but provide no form of ‘memory’ that would help the body fight off the disease at a future encounter. They can be composed of numerous entities including chemicals, proteins, or nucleic acids. Many drugs are used together to have a more substantial beneficial effect.
How do clinical trials work?
Clinical trials are the process by which new vaccines and drugs are approved to be used in the general population to help prevent, diagnose, or treat a disease. They are undertaken by healthcare professionals (including researchers and medical doctors) and often fall into five stages. Normally, it takes years or even decades for a compound to pass through clinical trials, but in extraordinary cases (such as pandemics) this process can be sped up to provide medical care to those in need while maintaining the highest standard of safety as well as. The five stages include:
Preclinical
In preclinical studies, researchers test the efficacy, toxicity, and other chemical information (absorption, distribution, metabolism, half-life, etc.) of a new drug. These studies are often done in test tubes and on cell cultures (in vitro/ex vivo) and in relevant animal models (in vivo). This process is done to determine which therapies have merit to move into the human testing stages.
Phase I
In phase I testing, a new therapeutic is given to healthy volunteers to assess its safety. Generally, multiple subtherapeutic doses are tested on between 20 - 100 individuals. This also provides an opportunity for researchers to assess the drug’s chemical properties in humans as these may differ from the in vitro and animal models.
Duration: Several Months
Success Rate: 70%
Phase II
Once the therapeutic has been deemed safe in healthy individuals, Phase II trials can commence. This is the first test where a drug/vaccine is administered to its target population and is done primarily to determine if the drug will be efficacious at its therapeutic dose. This clinical phase often has between 100 - 300 individuals, and it will not move onto the next phase until there is some data suggesting that the drug has some positive effect on the target population.
Duration: Several months to 2 years
Success Rate: 33%
Phase III
In Phase III clinical trials, the drug is now assumed to have some positive effect on its target population and more individuals are enrolled. Generally, between 300 - 3,000 individuals are taking part, and more rare, short-term side effects are able to be observed. Up to this point, mainly clinical researchers have been taking part in the clinical trials, but now personal physicians start to get involved as the therapeutic progress to the next stage.
Duration: 1 to 4 years
Success Rate: 25% - 30%
Phase IV
The purpose of Phase IV clinical trials (also known as postmarketing surveillance) is to watch for the long-term effects of the drugs on a larger population. The therapeutic at this point can be prescribed to any individual in the target population by their physician. Due to the longer term and larger subset of individuals using the therapeutic, extremely rare side effects can be observed.
How do pandemics impact the Clinical Trials Process?
When there is a serious, life-threatening situation where no medicine currently exists against a specific disease, such as during a pandemic, the clinical trial process may be expedited (or ‘Fast-Tracked’). This is generally only done with drugs that already show promise in combating the disease by having efficacy against related disorders. This process involves more regular meetings of the clinical trials governing body (ex. FDA) so that the drug can pass through stages faster, as well as the ability of the drug manufacturing company to submit sections of crucial documents as they are completed as opposed to once full stages of the trial are complete. Even in these circumstances, the clinical trial process is still extremely rigorous.
Where do your sources come from?
We use a combination of sources from legitimate governing bodies of clinical trial management, infectious disease specialists, and trusted research institutes. These references include:
The Center for Disease Control and Prevention (CDC):
https://www.cdc.gov/
The World Health Organization (WHO):
https://www.who.int/
And their DRAFT Landscape COVID-19 Candidate Vaccines list
https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
The National Institutes of Health (NIH):
https://www.nih.gov/
Clinical trial database:
https://clinicaltrials.gov/ct2/home
National Cancer Institute Drug Dictionary:
https://www.cancer.gov/publications/dictionaries/cancer-drug
The European Union Clinical Trials Register:
https://www.clinicaltrialsregister.eu/
The Food and Drug Administration:
https://www.fda.gov/
And their Clinical Trials Information Page:
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research#phases
The Chinese Clinical Trial Registry:
http://www.chictr.org.cn/enindex.aspx
Cytel Global Coronavirus COVID-19 Clinical Trial Tracker:
https://www.covid-trials.org/
The Milken Institute's COVID-19 Tracker:
https://milkeninstitute.org/covid-19-tracker
How did you make your images?
All of our illustrations are made with BioRender (that’s us!). BioRender is the world’s leading online application tool to help scientists create and share beautiful, professional scientific figures.
Can I republish or use your illustrations/data?
Please feel free to share our websites, templates and your own BioRender illustrations with friends on social media or around the web by citing ‘Created with BioRender.com’ (hyperlinked). You can also give us a shout out @BioRender! If you are sharing data only, we recommend you use the original source (CDC, WHO, etc.).
How can I provide feedback about this tracker?
We appreciate you browsing our vaccine tracker! If you'd like to give us any feedback on the content, data, or suggestions for improvement, please email us your feedback at vaccinetracker@biorender.com
Disclaimer
BioRender is currently tracking the development of vaccines and therapeutic drugs for COVID-19 (SARS-CoV-2). This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. While BioRender takes reasonable steps to verify the accuracy of the information presented in this page, we are not liable for any inaccuracies that may exist.
BioRender uses cookies to improve our user experience. By continuing to our site, you agree to our use of cookies outlined in our Privacy Policy.
Agree
© BioRender 2020
